Investors demand clarity from Fresenius over dialysis group FMC
FRANKFURT, May 17 (Reuters) -Investors demanded more clarity from German healthcare group Fresenius SE FREG.DE on Friday regarding its plans to cede strategic control over dialysis group Fresenius Medical Care FMEG.DE.
"The volatility at Fresenius Medical Care seems to repeatedly overshadow the recent positive operating developments at Fresenius and is also deterring many potential shareholders from investing in Fresenius," said Hendrik Schmidt, corporate governance expert at fund manager DWS.
Though the change to FMC's legal structure and the deconsolidation of Fresenius mark a first step, the complete separation is still pending and there is no clear timeline for the move, Schmidt said.
"Thus, despite the deconsolidation, the share price of Fresenius SE remains vulnerable to operational and strategic difficulties at Fresenius Medical Care."
Fresenius still holds a stake of around 32% in the dialysis specialist, which was deconsolidated at the end of November following a change to the legal structure.
FMC faced difficulties during the pandemic, with more dialysis patients than usual dying and a shortage of nursing staff. FMC thwarted the healthcare group's annual targets several times, but its performance is now improving.
Fresenius CEO Michael Sen, who took over in 2022, has been driving forward the realignment of the DAX-listed company and has sold various peripheral businesses.
Reporting by Patricia Weiss, Writing by Friederike Heine; editing by Matthias Williams
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
